OncoCyte Co. (NYSEAMERICAN:OCX) saw a large growth in short interest in December. As of December 29th, there was short interest totalling 477,222 shares, a growth of 47.1% from the December 15th total of 324,331 shares. Currently, 5.7% of the shares of the stock are short sold. Based on an average daily volume of 43,784 shares, the short-interest ratio is currently 10.9 days.
OncoCyte (OCX) opened at $4.20 on Friday. OncoCyte has a twelve month low of $3.60 and a twelve month high of $7.85. The company has a market capitalization of $131.99 and a PE ratio of -6.77.
OncoCyte (NYSEAMERICAN:OCX) last announced its earnings results on Tuesday, November 14th. The biotechnology company reported ($0.12) EPS for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.01.
OCX has been the topic of a number of research reports. ValuEngine lowered OncoCyte from a “hold” rating to a “sell” rating in a report on Thursday, October 5th. Zacks Investment Research downgraded OncoCyte from a “hold” rating to a “sell” rating in a research note on Saturday, November 18th.
TRADEMARK VIOLATION WARNING: This report was originally published by Week Herald and is owned by of Week Herald. If you are viewing this report on another website, it was illegally stolen and republished in violation of US and international trademark & copyright laws. The original version of this report can be accessed at https://weekherald.com/2018/01/20/oncocyte-co-ocx-short-interest-update.html.
OncoCyte Company Profile
OncoCyte Corporation is a development-stage biotechnology company focused in the field of regenerative medicine. The Company is developing molecular cancer diagnostics utilizing a discovery platform that focuses on identifying genetic markers expressed in various types of cancer. It operates through the research and development of diagnostic tests for the detection of cancer segment.
Receive News & Ratings for OncoCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoCyte and related companies with MarketBeat.com's FREE daily email newsletter.